At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients ...
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities ...
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and ...
Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for ...
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera ...
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC ...
Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.
Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn ...
Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for ...
Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine ...
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results